Literature DB >> 2900712

Psychosis, behavioral disturbance, and the use of neuroleptics in dementia.

D P Devanand1, H A Sackeim, R Mayeux.   

Abstract

Despite the widespread use of psychotropic agents in patients with dementia, there is little available research on the nature and prevalence of psychiatric disturbance and behavioral syndromes requiring this treatment, and the results of such therapy. The authors suggest strategies to overcome difficulties inherent in attempting to obtain symptom profiles in demented patients. There is weak evidence to support the use of neuroleptics in the treatment of symptoms like suspiciousness, hallucinations, sleeplessness, agitation, emotional liability, and aggressiveness; no individual neuroleptic can be considered superior to any other for this purpose. Few studies have evaluated the effect of neuroleptics on activities of daily life (ADL), and no study has used detailed neurophsychological evaluation to examine their effects on cognitive function in dementia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900712     DOI: 10.1016/0010-440x(88)90020-x

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  5 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Neuroleptic prescribing in residents of nursing homes. Use may be justified if other factors have been considered.

Authors:  R Tobiansky; M Blanchard
Journal:  BMJ       Date:  1996-06-29

4.  Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses.

Authors:  R T Koopmans; J M van Rossum; H J van den Hoogen; Y A Hekster; M A Willekens-Bogaers; C van Weel
Journal:  Pharm World Sci       Date:  1996-01

Review 5.  The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies.

Authors:  S McGaffigan; D L Bliwise
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.